Page last updated: 2024-08-25

rosiglitazone and 2,4-thiazolidinedione

rosiglitazone has been researched along with 2,4-thiazolidinedione in 78 studies

Research

Studies (78)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.56)	18.2507
2000's	52 (66.67)	29.6817
2010's	21 (26.92)	24.3611
2020's	3 (3.85)	2.80

Authors

Authors	Studies
Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K	1
Fleck, E; Goetze, S; Gotlibowski, T; Hsueh, WA; Kawano, H; Law, RE; Xi, XP	1
Adams, M; Agostini, M; Browne, PO; Burris, TP; Chatterjee, VK; Collingwood, TN; Gurnell, M; Lazar, MA; Provenzano, C; Rajanayagam, O; Schwabe, JW; Wentworth, JM	1
Kuzuya, T	1
Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM	1
Bilakovics, J; Croston, GE; Faulkner, A; Hoener, PA; Jow, L; Klausing, K; Mais, DE; Mukherjee, R; Paterniti, JR	1
Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C	1
Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S	1
Albrektsen, T; Fleckner, J	1
Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM	1
Banerji, MA; Lebovitz, HE	1
Berger, J; Elbrecht, A; Hermanowski-Vosatka, A; Moller, DE; Tanen, M; Thieringer, R; Wright, SD	1
Janka, HU	1
Hayashi, T; Hosoda, K; Inoue, G; Inoue, R; Masuzaki, H; Nakao, K; Nishimura, H; Ogawa, Y; Shintani, M; Yamamoto, Y; Yonemitsu, S	1
Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y	1
Boscá, L; Castrillo, A; Hortelano, S; Mojena, M	1
Csermely, P; Jermendy, G	1
Jazet, IM; Meinders, AE	1
Brown, JM; Geigerman, C; Halvorsen, YD; Lea-Currie, YR; McIntosh, M	1
Iwata, Y; Kasuya, A; Miyamoto, S; Takamura, M; Yanagisawa, H	1
Pospísilová, Y	1
Beale, EG; Duplus, E; Forest, C; Glorian, M; Granner, DK; Scott, DK	1
Scheen, AJ	1
Hiraoka, S; Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Takakura, R; Toyota, M	1
Blows, F; O'Rahilly, S; Sewter, CP; Vidal-Puig, A	1
Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ	1
Greenberg, AS; Pittas, AG	1
Albrektsen, T; Boysen, MS; Fleckner, J; Grøntved, L; Helledie, T; Jensen, SS; Kiilerich, P; Kristiansen, K; Larsen, LK; Mandrup, S; Nøhr, J; Rietveld, L; Stunnenberg, HG	1
Frauwirth, KA; Lazar, MA; Rangwala, SM; Thompson, CB; Wang, YL	1
Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM	1
Häring, HU; Stumvoll, M	1
Bradley, C	1
LaCivita, KA; Villarreal, G	1
Dey, CS; Kumar, N	1
Flodgren, E; Kotarsky, K; Nilsson, NE; Olde, B; Owman, C	1
Bolusu, G; Chakrabarti, R; Gershome, C; Hiriyan, J; Juluri, S; Kashireddy, P; Misra, P; Qi, C; Rajjak, A; Ramanujam, R; Rao, MS; Reddy, JK; Surapureddi, S; Vikramadithyan, RK; Yu, S; Zhu, YJ	1
Armoni, M; Bar-Yoseph, F; Chen, H; Harel, C; Karnieli, E; Kritz, N; Quon, MJ	1
Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL	1
Accili, D; Carnemolla, R; Han, S; Liang, CP; Okamoto, H; Tabas, I; Tall, AR	1
Béréziat, V; Burnol, AF; Capitaine, N; Cariou, B; Girard, J; Kergoat, M; Laville, M; Le Marcis, V; Vega, N; Vidal, H	1
Aebersold, R; Berger, JP; Collins, SJ; Dai, H; Doyle, MJ; Eng, J; Feetham, MC; Goodlett, D; Gunter, B; Hanlon, WA; Hood, LE; Linseley, PS; Mao, M; Stepaniants, SB; Stoughton, RB; Thorsson, V; Tian, Q; Weng, L; Yi, EC	1
Ahmad, H; Brown, RD; Fox, J; Gen, M; Greyson, C; Long, CS; Lu, L; Perlov, D; Schwartz, GG; Weiss, SO; Xu, Y; Zhu, P	1
Gavrilova, O; Haluzik, M; Kim, H; LeRoith, D; Pajvani, UB; Portas, J; Scherer, PE; Sun, H; Yakar, S	1
Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H	1
Brandt, U; Brüne, B; Dröse, S; Soller, M; von Knethen, A	1
Bryant, B; Jain, SK; Yaturu, S	1
Batra, RK; Cui, X; Dubinett, SM; Hazra, S; Sharma, S; Tai, HH	1
Goldberg, RA; Lee, S; McCann, JD; Tsirbas, A	1
Schwartz, AV; Sellmeyer, DE	1
Aggerbeck, M; Antoine, B; Barouki, R; Chapron, C; Chauvet, C; Chauvet, G; Forest, C; Leroyer, S; Quette, J; Tomkiewicz, C; Tordjman, J	1
Allred, CD; Kilgore, MW; Southard, RC; Talbert, DR; Wang, X	1
Chen, JL; Escaron, P; Furukawa, N; Learned, RM; Lee, G; Li, Y; Lindstrom, M; Liu, J; Liu, X; Plotnikova, O; Prasad, V; Walker, N; Wang, Z; Weiszmann, J; Xu, H	1
Bugaj, V; Cunard, R; Dechenes, G; Hummler, E; Pochynyuk, O; Rieg, T; Rossier, B; Schroth, J; Stockand, J; Vallon, V	1
Anastasilakis, AD; Goulis, DG; Toulis, KA	1
Krumholz, HM	1
Arondekar, B; Darkow, TE; Harley, C; Thayer, S	1
Alves de Lima, Mdo C; Amato, AA; Barros, CD; de Oliveira, TB; Galdino, SL; Hernandes, MZ; Iannini, KB; Leite, ES; Neves, Fde A; Pitta, Ida R; Silva, AL; Silva, TG	1
Anand, S; Bailey, SD; Diaz, R; Do, R; Engert, JC; Gerstein, HC; Keavney, B; Mohan, V; Montpetit, A; Xie, C; Yusuf, S	1
Chang, C; Chang, CP; Chen, CM; Chen, HM; Chen, HW; Chern, Y; Chiang, MC; Hung, CH; Kang, JJ; Lee, MR; Tsai, YS; Wu, YR; Wu, YS	1
Bu, SY; Chen, X; Guo, H; Hannaford, J; Jin, D; Mashek, DG; Zhang, Y	1
Curtis, B; Hall, GC; McMahon, AD; Smith, HT	1
Haq, W; Katti, SB; Raghubir, R; Raza, S; Samuel, SS; Verma, R	1
Banks, AS; Bruning, JB; Busby, SA; Cameron, MD; Chalmers, MJ; Choi, JH; Griffin, PR; He, Y; Jurczak, MJ; Kamenecka, TM; Kumar, N; Kuruvilla, DS; Laznik, D; Marciano, DP; Schürer, SC; Shin, Y; Shulman, GI; Spiegelman, BM; Vidović, D	1
Chern, Y; Chiang, MC; Huang, RN	1
Carta, AR; Pisanu, A	1
Carson, DD; Engel, BJ	1
Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK	1
Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, KK; Shafi, S; Yar, MS	1
Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y	1
Ding, RG; Fan, X; Hu, D; Li, ZJ; Liu, Y; Wang, QJ; Wu, CQ	1
Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, K; Shahar Yar, M	1
Bu, Y; Yu, J	1
Elstner, E; Khoo, BY; Miswan, N; Nadarajan, K; Possinger, K; Shim, SY; Zang, CB	1
Colca, JR; Cole, SL; Finck, BN; Hodges, WT; Kletzien, RF; McCommis, KS; McDonald, WG; Oonthonpan, L; Schweitzer, GG; Taylor, EB; Vigueira, PA	1
Area-Gomez, E; Chan, M; Creusot, RJ; Fan, L; Fu, W; Ji, R; Kon, N; Kraakman, MJ; Larrea, D; Liu, Q; Namwanje, M; Postigo-Fernandez, J; Qiang, L	1
Abaalkhail, SJ; Al Shhab, M; El Madani, A; Jamous, Y; Jarrar, Q; Jarrar, YB; Lee, SJ; Moh'd Kalloush, H; Naser, W; Zihlif, M	1
Arineitwe, C; Khanye, S; Khathi, A; Oderinlo, O; Sibiya, N; Tukulula, M	1
Ahsan, W; Alam, MS; Albratty, M; Alhazmi, HA; Azam, F; Haque, A; Meraya, AM; Najmi, A; Taha, MME; Thangavel, N	1

Reviews

12 review(s) available for rosiglitazone and 2,4-thiazolidinedione

Article	Year
[The development of thiazolidinedione drugs as anti-diabetic agents]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2000
Insulin resistance and its treatment by thiazolidinediones. Recent progress in hormone research, 2001, Volume: 56 Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[Glitazones. Profile of a new class of substances]. Der Internist, 2001, Volume: 42, Issue:4 Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States	2001
[Thiazolidinediones--a new class of oral antidiabetic drugs]. Orvosi hetilap, 2001, Jul-22, Volume: 142, Issue:29 Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents]. Nederlands tijdschrift voor geneeskunde, 2001, Aug-11, Volume: 145, Issue:32 Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001
[News in oral antidiabetic therapy]. Vnitrni lekarstvi, 2001, Volume: 47, Issue:9 Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones	2001
Hepatotoxicity with thiazolidinediones: is it a class effect? Drug safety, 2001, Volume: 24, Issue:12 Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone	2001
Thiazolidinediones in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:5 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Glitazones: clinical effects and molecular mechanisms. Annals of medicine, 2002, Volume: 34, Issue:3 Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2002
The glitazones: a new treatment for type 2 diabetes mellitus. Intensive & critical care nursing, 2002, Volume: 18, Issue:3 Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom	2002
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgraduate medicine, 2003, Volume: Spec No Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones	2003
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotoxicity research, 2013, Volume: 23, Issue:2 Topics: Animals; Antiparkinson Agents; Encephalitis; Humans; Microglia; Parkinson Disease; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones	2013

Other Studies

66 other study(ies) available for rosiglitazone and 2,4-thiazolidinedione

Article	Year
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships. Chemical & pharmaceutical bulletin, 1997, Volume: 45, Issue:12 Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone	1997
PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Journal of cardiovascular pharmacology, 1999, Volume: 33, Issue:5 Topics: Animals; Aorta, Thoracic; Calcium-Calmodulin-Dependent Protein Kinases; Cell Movement; Cells, Cultured; Chemotactic Factors; Chromans; Cycloheximide; Dactinomycin; Enzyme Activation; Insulin-Like Growth Factor I; Ligands; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Prostaglandin D2; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thrombin; Transcription Factors; Troglitazone	1999
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. The Journal of biological chemistry, 2000, Feb-25, Volume: 275, Issue:8 Topics: Adenoviridae; Adipocytes; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Genes, Dominant; Genetic Vectors; Humans; Ligands; Models, Biological; Mutation; Nuclear Receptor Co-Repressor 2; Plasmids; Precipitin Tests; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection	2000
Information on thiazolidinediones. Lancet (London, England), 2000, Jul-15, Volume: 356, Issue:9225 Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration	2000
A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:9 Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Adipocytes; Animals; Benzoates; Cell Differentiation; Cell Line; Dexamethasone; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Ligands; Mice; Naphthalenes; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Proteins; Retinoid X Receptors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Triglycerides; Tumor Necrosis Factor-alpha	2000
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. The Journal of clinical investigation, 2000, Volume: 106, Issue:10 Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, Animal; Female; Hypoglycemic Agents; Insulin; Ligands; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Respiratory Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone	2000
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:12 Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Nicotinic Acids; Obesity; Proteins; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Weight Gain	2000
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells. Molecular pharmacology, 2001, Volume: 59, Issue:3 Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation	2001
The hormone resistin links obesity to diabetes. Nature, 2001, Jan-18, Volume: 409, Issue:6818 Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones	2001
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. The Journal of biological chemistry, 2001, Apr-20, Volume: 276, Issue:16 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3 Cells; Adipocytes; Animals; Cycloheximide; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Hydroxysteroid Dehydrogenases; Kinetics; Leptin; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic	2001
Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes, 2001, Volume: 50, Issue:5 Topics: Animals; Biological Transport; Cell Line; Cell Membrane; Chromans; Cycloheximide; Deoxyglucose; Gene Expression Regulation; Glucose Transporter Type 1; Glucose Transporter Type 3; Glucose Transporter Type 4; Insulin; Kinetics; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nerve Tissue Proteins; Protein Transport; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone	2001
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. European journal of pharmacology, 2001, Jun-29, Volume: 423, Issue:1 Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	2001
Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2). The Journal of biological chemistry, 2001, Sep-07, Volume: 276, Issue:36 Topics: Anions; Apoptosis; Benzofurans; Blotting, Northern; Blotting, Western; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cytosol; Dose-Response Relationship, Drug; Flow Cytometry; Genes, Reporter; Glutathione Transferase; I-kappa B Kinase; Immunohistochemistry; Kinetics; Ligands; Macrophage Activation; Macrophages; Microscopy, Confocal; NF-kappa B; Nitric Oxide; Phenylacetates; Plasmids; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transfection	2001
Trans-10, cis-12, but not cis-9, trans-11, conjugated linoleic acid attenuates lipogenesis in primary cultures of stromal vascular cells from human adipose tissue. The Journal of nutrition, 2001, Volume: 131, Issue:9 Topics: Adipose Tissue; Blood Vessels; Cells, Cultured; Dose-Response Relationship, Drug; Glucose; Humans; Linoleic Acid; Lipids; Lipolysis; Osmolar Concentration; Rosiglitazone; Stereoisomerism; Stromal Cells; Thiazoles; Thiazolidinediones; Triglycerides	2001
Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. Journal of molecular graphics & modelling, 2001, Volume: 19, Issue:6 Topics: Hypoglycemic Agents; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Oximes; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors	2001
A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie, 2001, Volume: 83, Issue:10 Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Carcinoma, Hepatocellular; Gene Expression; Hypoglycemic Agents; Male; Mice; Phosphoenolpyruvate Carboxykinase (GTP); Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Repetitive Sequences, Nucleic Acid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured	2001
PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. International journal of cancer, 2001, Nov-01, Volume: 94, Issue:3 Topics: Animals; Blotting, Northern; Blotting, Western; Cell Division; Cell Line; Cell Line, Transformed; Cell Nucleus; Chromans; Cyclin D1; DNA, Complementary; Dose-Response Relationship, Drug; Epidermal Growth Factor; Epithelial Cells; Flow Cytometry; Humans; Hypoglycemic Agents; Intestines; Ligands; Luciferases; Plasmids; Promoter Regions, Genetic; ras Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Troglitazone	2001
Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes, 2002, Volume: 51, Issue:3 Topics: Adipocytes; Adult; Aged; Cell Differentiation; Female; Gene Expression; Humans; Hypoglycemic Agents; Ligands; Male; Middle Aged; Nicotinic Acids; Omentum; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Skin; Stem Cells; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors	2002
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes, 2002, Volume: 51, Issue:4 Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors	2002
The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. The Journal of biological chemistry, 2002, Jul-26, Volume: 277, Issue:30 Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Nucleus; Chromatin; Cross-Linking Reagents; Diazepam Binding Inhibitor; Fibrinolytic Agents; Gene Expression Regulation; Genes, Reporter; Humans; Introns; Ligands; Liver; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Precipitin Tests; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors	2002
Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. The Journal of biological chemistry, 2002, Aug-30, Volume: 277, Issue:35 Topics: Animals; Cell Death; Cell Survival; Cells, Cultured; Humans; Hypoglycemic Agents; Interleukin-3; Lymphocyte Activation; Membrane Potentials; Mice; Mice, Inbred C57BL; Mitochondria; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Up-Regulation	2002
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:7 Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones	2002
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Current medical research and opinion, 2002, Volume: 18, Issue:6 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides	2002
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochemical pharmacology, 2003, Jan-15, Volume: 65, Issue:2 Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine	2003
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochemical and biophysical research communications, 2003, Feb-07, Volume: 301, Issue:2 Topics: Aequorin; Animals; Calcium; Cell Line; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Genes, Reporter; Humans; Hypoglycemic Agents; Islets of Langerhans; Mice; Palmitic Acids; Receptors, Cell Surface; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution	2003
PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:2 Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Carrier Proteins; Cyclic AMP Response Element-Binding Protein; Histone Acetyltransferases; Hypoglycemic Agents; Mediator Complex Subunit 1; Mice; Nuclear Receptor Coactivator 1; Pyridines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors	2003
Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. The Journal of biological chemistry, 2003, Aug-15, Volume: 278, Issue:33 Topics: Adipocytes; Animals; CHO Cells; Cricetinae; Dimerization; Fibroblasts; Gene Expression Regulation; Genetic Complementation Test; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Immunologic Factors; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Promoter Regions, Genetic; Prostaglandin D2; Protein Structure, Tertiary; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Suppression, Genetic; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic	2003
Increased CD36 protein as a response to defective insulin signaling in macrophages. The Journal of clinical investigation, 2004, Volume: 113, Issue:5 Topics: Animals; Blotting, Northern; Blotting, Western; CD36 Antigens; Chromones; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Foam Cells; Glutathione; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Morpholines; Oxygen; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Tyrosine	2004
Increased adipose tissue expression of Grb14 in several models of insulin resistance. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:9 Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Insulin; Insulin Resistance; Liver; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2004
Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Molecular & cellular proteomics : MCP, 2004, Volume: 3, Issue:10 Topics: Animals; Cell Line; Culture Media, Conditioned; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation; Genetic Variation; Genomics; Hematopoietic Stem Cells; Kinetics; Liver; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Myelopoiesis; Oligonucleotide Array Sequence Analysis; Peroxisome Proliferator-Activated Receptors; Peroxisome Proliferators; Protein Processing, Post-Translational; Proteins; Proteomics; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2004
PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:3 Topics: alpha-Tocopherol; Animals; Antioxidants; Chromans; Coronary Circulation; Cytokines; Energy Metabolism; Fatty Acids, Nonesterified; Female; Hypoglycemic Agents; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; PPAR gamma; RNA, Messenger; Rosiglitazone; Sus scrofa; Thiazolidinediones; Troglitazone; Ventricular Function, Left	2005
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia, 2004, Volume: 47, Issue:12 Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones	2004
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America, 2005, Jun-28, Volume: 102, Issue:26 Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; Evans Blue; Gene Deletion; Genotype; Heterozygote; Hypoglycemic Agents; Immunohistochemistry; Integrases; Kidney; Kidney Tubules, Collecting; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nephrons; PPAR gamma; Promoter Regions, Genetic; Radioimmunoassay; Rosiglitazone; Sodium; Thiazolidinediones	2005
Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Adenosine Triphosphate; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Chromans; Humans; Jurkat Cells; Mitochondria; Necrosis; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Troglitazone	2007
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Humans; Hydroxyprostaglandin Dehydrogenases; Hypoglycemic Agents; Membrane Proteins; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Up-Regulation	2007
Thiazolidinedione induced thyroid associated orbitopathy. BMC ophthalmology, 2007, Apr-26, Volume: 7 Topics: Diplopia; Disease Progression; Drug Therapy, Combination; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Metformin; Middle Aged; Propranolol; Propylthiouracil; Retreatment; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes care, 2007, Volume: 30, Issue:6 Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione. The Journal of biological chemistry, 2007, Aug-10, Volume: 282, Issue:32 Topics: Adipocytes; Adipose Tissue; Animals; Aspartate Aminotransferases; Base Sequence; Cytosol; Humans; Hypoglycemic Agents; Mice; Molecular Sequence Data; NIH 3T3 Cells; Nuclear Receptor Subfamily 1, Group F, Member 1; PPAR gamma; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Trans-Activators	2007
PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. The Journal of nutrition, 2008, Volume: 138, Issue:2 Topics: Anilides; Cell Proliferation; Colonic Neoplasms; Eicosapentaenoic Acid; Gene Expression Regulation; HT29 Cells; Humans; Male; PPAR gamma; Prostatic Neoplasms; Protein Binding; Response Elements; Rosiglitazone; Thiazolidinediones	2008
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. The Journal of biological chemistry, 2008, Apr-04, Volume: 283, Issue:14 Topics: Adipocytes; Adipogenesis; Animals; Benzothiazoles; Binding Sites; Cells, Cultured; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Ligands; Mice; Models, Molecular; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Weight Gain	2008
Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:4 Topics: Animals; Epithelial Sodium Channels; Kidney Medulla; Kidney Tubules, Collecting; Mice; Patch-Clamp Techniques; Pioglitazone; Rosiglitazone; Thiazolidinediones; Weight Gain	2009
Thiazolidinedione use and the risk of fractures. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2009, Apr-14, Volume: 180, Issue:8 Topics: Bone Density; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Greece; Humans; Hypoglycemic Agents; Incidence; Male; Odds Ratio; Pioglitazone; Reference Values; Risk Assessment; Rosiglitazone; Thiazolidinediones	2009
A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:3 Topics: Advisory Committees; American Heart Association; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Pioglitazone; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones; United States	2010
Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5 Topics: Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Drug Utilization; Humans; Hypoglycemic Agents; Patient Compliance; Retrospective Studies; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2010
Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands. Bioorganic & medicinal chemistry, 2010, Jun-01, Volume: 18, Issue:11 Topics: Anti-Inflammatory Agents; Binding, Competitive; Computer Simulation; Humans; Ligands; PPAR gamma; Protein Binding; Rosiglitazone; Structure-Activity Relationship; Sulfones; Thiazolidinediones	2010
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes care, 2010, Volume: 33, Issue:10 Topics: Diabetes Mellitus, Type 2; Edema; Female; Humans; Hypoglycemic Agents; Male; NFATC Transcription Factors; Polymorphism, Single Nucleotide; Ramipril; Rosiglitazone; Thiazolidinediones	2010
Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Human molecular genetics, 2010, Oct-15, Volume: 19, Issue:20 Topics: Adipocytes; Animals; Brain; Down-Regulation; Energy Metabolism; Gene Expression Regulation; Glucose Transporter Type 4; Humans; Huntington Disease; Liver; Lymphocytes; Mice; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Polymerase Chain Reaction; PPAR gamma; Rosiglitazone; Thiazolidinediones; Trans-Activators; Transcription Factors	2010
Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:2 Topics: Acute-Phase Proteins; Adipocytes; Adipose Tissue, Brown; Animals; Dietary Fats; Energy Metabolism; Homeostasis; Hypoglycemic Agents; Lipid Metabolism; Lipocalin-2; Lipocalins; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Oncogene Proteins; PPAR gamma; Rosiglitazone; Thiazolidinediones	2011
Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning. International journal of clinical practice, 2011, Volume: 65, Issue:5 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Practice Patterns, Physicians'; Risk Factors; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United Kingdom	2011
Anti-stroke profile of thiazolidin-4-one derivatives in focal cerebral ischemia model in rat. Chemical biology & drug design, 2011, Volume: 78, Issue:3 Topics: Animals; Brain; Brain Ischemia; Excitatory Amino Acid Transporter 2; Glutamic Acid; Glutathione; Male; Neuroprotective Agents; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2011
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature, 2011, Sep-04, Volume: 477, Issue:7365 Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Animals; Biphenyl Compounds; Body Fluids; Chlorocebus aethiops; COS Cells; Cyclin-Dependent Kinase 5; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Obesity; Osteogenesis; Phosphorylation; Phosphoserine; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha; Weight Gain	2011
PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. Neurobiology of disease, 2012, Volume: 45, Issue:1 Topics: Animals; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Energy Metabolism; Huntington Disease; Male; Mice; Mice, Transgenic; Mitochondria; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Trinucleotide Repeat Expansion	2012
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines. Journal of cellular biochemistry, 2013, Volume: 114, Issue:10 Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms	2013
Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes care, 2014, Volume: 37, Issue:5 Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States	2014
Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists. European journal of medicinal chemistry, 2014, Nov-24, Volume: 87 Topics: Animals; Blood Glucose; Computer Simulation; Diabetes Mellitus, Experimental; Drug Design; Female; Gene Expression Regulation; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Liver; Male; Molecular Docking Simulation; Molecular Structure; Oxadiazoles; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones	2014
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes. Experimental dermatology, 2015, Volume: 24, Issue:1 Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone	2015
Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. Toxicology and applied pharmacology, 2015, Apr-15, Volume: 284, Issue:2 Topics: Cell Line, Tumor; Chromans; DNA, Mitochondrial; Electron Transport; Humans; Hypoglycemic Agents; Liver; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Pioglitazone; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Troglitazone	2015
Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists. Archiv der Pharmazie, 2015, Volume: 348, Issue:6 Topics: 3T3-L1 Cells; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Female; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Molecular Docking Simulation; Molecular Structure; Pioglitazone; PPAR gamma; Protein Binding; Rats, Wistar; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transfection	2015
[Rosiglitazone protects against endotoxin-induced acute liver injury in rats]. Zhonghua yi xue za zhi, 2015, Oct-20, Volume: 95, Issue:39 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cytokines; Endotoxins; Liver; Rats; Rosiglitazone; Sepsis; Thiazolidinediones	2015
Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF‑7 cells by reducing FGF4 protein expression. Molecular medicine reports, 2016, Volume: 13, Issue:4 Topics: Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Conditioned; Cytokines; Down-Regulation; Fibroblast Growth Factor 4; Gene Expression Regulation; Humans; Ki-67 Antigen; MCF-7 Cells; Mesenchymal Stem Cells; Pioglitazone; Proliferating Cell Nuclear Antigen; Rosiglitazone; Thiazolidinediones	2016
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Experimental physiology, 2017, 08-01, Volume: 102, Issue:8 Topics: Acetophenones; Adipose Tissue; Animals; Anion Transport Proteins; Diet, High-Fat; Hypoglycemic Agents; Insulin; Insulin Resistance; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Pioglitazone; PPAR gamma; Proprotein Convertase 2; Rosiglitazone; Thiazolidinediones	2017
PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. The Journal of clinical investigation, 2018, 06-01, Volume: 128, Issue:6 Topics: Acetylation; Adipose Tissue, White; Animals; Body Weight; Energy Metabolism; Female; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones	2018
Molecular toxicological alterations in the mouse hearts induced by sub-chronic thiazolidinedione drugs administration. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:1 Topics: Animals; Glycoproteins; Hypoglycemic Agents; Mice; Pharmaceutical Preparations; Phosphoproteins; Rosiglitazone; Thiazolidinediones	2022
Discovery of Novel Thiazolidinedione-Derivatives with Multi-Modal Antidiabetic Activities In Vitro and In Silico. International journal of molecular sciences, 2023, Feb-03, Volume: 24, Issue:3 Topics: Glucose; Hypoglycemic Agents; Molecular Docking Simulation; PPAR gamma; Rosiglitazone; Thiazolidinediones	2023
Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists. Scientific reports, 2023, 11-14, Volume: 13, Issue:1 Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Mice; Molecular Docking Simulation; PPAR gamma; PPAR-gamma Agonists; Rosiglitazone; Thiazolidinediones; Weight Gain	2023